Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational ...

Truist Securities analyst initiates Buy rating & $24 price target for BKV Corporation, owned by Banpu with potential for ...

BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before markets open on Tuesday ...

DENVER, October 30, 2024--(BUSINESS WIRE)--BKV Corporation (NYSE: BKV) ("BKV" or the "Company") today announced that it will report its third quarter 2024 operational and financial results before ...

BKV Corporation (NYSE:BKV – Get Free Report) has been given an average recommendation of “Buy” by the eight analysts that are ...

Fintel reports that on October 25, 2024, Truist Securities initiated coverage of BKV (NYSE:BKV) with a Buy recommendation.

DENVER--(BUSINESS WIRE)--BKV Corporation (NYSE: BKV) (“BKV” or the “Company”) today announced that it will report its third quarter 2024 operational and financial results before markets ...

Analysts at KeyCorp issued their Q3 2024 earnings estimates for shares of BKV in a research note issued to investors on ...

Fintel reports that on October 22, 2024, Susquehanna initiated coverage of BKV (NYSE:BKV) with a Positive recommendation.

Truist Securities analyst Bertrand Donnes initiated coverage on BKV Corporation (NYSE:BKV) with a Buy rating and a price target of $24. The analyst writes that BKV is primarily owned by parent ...

Truist analyst Bertrand Donnes initiated coverage of BKV Corp. (BKV) with a Buy rating and $24 price target The SMID-cap energy company has ...